To evaluate the complementary effect of whey protein for treatment of diabetes type II

To evaluate the efficacy and side effects of using the Ma-al-Jobn in treatment of diabetic type II patients as a complementary therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140715018490N4

Enrollment

Registered

2018-07-20

Start date

2018-07-23

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Drug group: In addition to anti-diabetes medications, patients in this group should receive a sachet of whey protein powder (12.5 g. each) in 150-200 cc of hot water every day. They ar

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Presence of diabetes (FBS>126 mg/dl) Have a FBS less than 250 and HgbA1c more than 6.4 Age between 30 to 65 years No systemic diseases like; liver, renal, rheumatologic diseases or hypertension No consume any anti-diabetic or corticosteroid drugs 2 weeks before the study No drink alcohol or use opium Weight less than 100 kg Have a BMI less than 35

Exclusion criteria

Exclusion criteria: No agree to participate in the study Have a FBS more than 270 mg/dl Consuming corticosteroid drugs during the study Presence of any side effects

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;HgbA1C. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;Total cholesterol. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;BS2pp. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;LDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;HDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;SGOT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;SGPT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;Alp. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;TG. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.	—

Measure

Time frame

FBS. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;HgbA1C. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;Total cholesterol. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;BS2pp. Timepoint: At the beginning of intervention, after 2 weeks then after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;LDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;HDL. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;SGOT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;SGPT. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;Alp. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.;TG. Timepoint: At the beginning of intervention and after 12 weeks from the beginning of intervention. Method of measurement: Venous blood sampling.

—

Secondary

Measure	Time frame
Satisfaction of patients. Timepoint: 3 months after recruitment. Method of measurement: visual analog scale.;Tolerance. Timepoint: 3 months after recruitment. Method of measurement: visual analog scale.;Temperament. Timepoint: At the beginning of the study. Method of measurement: Questionnaire.;Drug side effects. Timepoint: 3 months after recruitment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMassih Sedigh Rahimabadi

Fasa University of Medical Sciences

massih21@yahoo.com+98 71 3825 6275

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026